Revenue and Profit - Revenue for Q3 2022 reached ¥9,469,539,012.34, an increase of 9.38% year-over-year, while year-to-date revenue was ¥27,823,286,821.00, up 27.46% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2022 was ¥1,878,137,901.60, a decrease of 35.52% year-over-year, with year-to-date net profit at ¥5,607,155,253.07, down 33.28%[3] - Basic earnings per share for Q3 2022 was ¥1.1738, reflecting a decline of 35.53% compared to the same period last year[3] - The company's net profit for the third quarter of 2022 was CNY 5,607,155,253.07, compared to CNY 8,403,607,789.29 in the same quarter of the previous year, reflecting a decrease of approximately 33.5%[21] - The net profit attributable to the parent company for Q3 2022 was CNY 5,607,155,253.07, a decrease of 33.7% from CNY 8,403,607,789.29 in the same period last year[22] - The company’s total comprehensive income for Q3 2022 was CNY 5,607,155,253.07, reflecting a decline of 33.7% from CNY 8,403,607,789.29 in the previous year[22] Assets and Liabilities - Total assets as of the end of Q3 2022 amounted to ¥36,227,856,518.53, representing a 20.57% increase from the end of the previous year[4] - The total liabilities as of September 30, 2022, were CNY 13,923,488,353.63, compared to CNY 12,390,110,553.53 at the beginning of the year, representing an increase of approximately 12.4%[20] - The total equity attributable to shareholders rose to ¥22,304,368,164.90, a 26.32% increase from the previous year[4] - The total equity attributable to shareholders of the parent company reached CNY 22,304,368,164.90, up from CNY 17,657,212,911.83 at the beginning of the year, indicating an increase of about 26.9%[20] Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net amount of ¥989,225,797.01, down 88.11% year-to-date[3] - The net cash flow from operating activities was ¥989,225,797.01, an 88.11% decrease from ¥8,321,407,156.74 in the previous period, mainly due to increased payments for goods[11] - The net cash flow from financing activities was -¥1,453,367,548.21, a 62.14% improvement from -¥3,838,489,899.06 in the previous period, primarily due to an increase in short-term borrowings received[11] - Cash inflow from operating activities for the period was CNY 22,468,907,315.97, an increase of 19.0% compared to CNY 18,778,634,686.71 in the previous year[23] - Cash outflow from operating activities totaled CNY 21,479,681,518.96, up from CNY 10,457,227,529.97, indicating a significant increase in operational expenses[23] - The net cash flow from financing activities was -CNY 1,453,367,548.21, an improvement from -CNY 3,838,489,899.06 in the same period last year[24] - The ending cash and cash equivalents balance was CNY 2,663,776,410.21, down from CNY 4,244,270,666.85, indicating a decrease in liquidity[24] Research and Development - Research and development expenses for Q3 2022 increased by 152.77% to ¥607,498,775.07, indicating a strong focus on innovation[9] - Research and development expenses increased significantly to CNY 607,498,775.07 from CNY 240,340,975.29 year-on-year, marking an increase of about 152.5%[21] Inventory and Receivables - Accounts receivable increased by 46.87% to ¥18,898,354,770.39, primarily due to higher sales revenue[8] - Inventory as of September 30, 2022, was CNY 8,067,216,185.86, up from CNY 7,385,396,274.99 at the beginning of the year, indicating an increase of about 9.2%[19] Borrowings and Financing - The company reported a significant increase in short-term borrowings, which rose by 228.24% to ¥1,867,200,500.65, reflecting increased financing needs[8] - The company's short-term borrowings rose significantly to CNY 1,867,200,500.65 from CNY 568,858,956.43, representing an increase of approximately 228.5%[19] Vaccine Production - The company issued 2.69 million units of ACYW135 polysaccharide vaccine and 4.36 million units of AC conjugate vaccine during the reporting period, indicating ongoing commitment to the vaccine market[16] - The four-valent HPV vaccine saw a significant increase in issuance, with 11.81 million units issued, representing a 158% year-on-year growth[16] - The nine-valent HPV vaccine issuance reached 12.28 million units, reflecting a 128% year-on-year increase[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 92,353, with the largest shareholder holding 48.32% of the shares[12] - The company's cash and cash equivalents decreased to ¥2,672,454,279.80 from ¥4,307,751,548.35 at the beginning of the year, indicating a significant reduction in liquidity[17]

重庆智飞生物制品股份有限公司 2022 年半年度报告全文 重庆智飞生物制品股份有限公司 2022 年半年度报告 2022 年 8 月 1 重庆智飞生物制品股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人蒋仁生、主管会计工作负责人李振敬及会计机构负责人(会计 主管人员)蒋彩莲声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成公司 对投资者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识， 并且应当理解计划、预测与承诺之间的差异。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 重庆智飞生物制品股份有限公司 2022 年半年度报告全文 本公司请投资者认真阅读本报告全文，并特别注意下列风险因素： 1、产品研发不达预期的风险 依托雄厚的研发实力，公司在研项目储备丰富，产品研发梯次合理。由 于生物制品研发具有 ...

重庆智飞生物制品股份有限公司 2022 年第一季度报告全文 证券代码：300122 证券简称：智飞生物 公告编号：2022-32 重庆智飞生物制品股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 本报告期 上年同期 本报告期比上年同期增减 | --- | --- | --- | --- | |-----------------------------------------------------|-------------------|------------------|------------ ...

重庆智飞生物制品股份有限公司 2021 年年度报告全文 重庆智飞生物制品股份有限公司 2021 年年度报告 2022 年 04 月 1 重庆智飞生物制品股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及全体董事、监事、高级管理人员保证年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别 和连带的法律责任。 公司负责人蒋仁生、主管会计工作负责人李振敬及会计机构负责人(会计主 管人员)蒋彩莲声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成公司对 投资者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且 应当理解计划、预测与承诺之间的差异。 公司经本次董事会审议通过的利润分配预案为：以 1,600,000,000 股为基数， 向全体股东每 10 股派发现金红利 6.00 元（含税），送红股 0 股（含税），以资本 公积金向全体股东每 10 股转增 0 股。 2 重庆智飞生物制品股份有限公司 2021 年年度报告全文 本公司请投资者 ...